Fleury S.A. Logo

Fleury S.A.

FLRY3.SA

(2.8)
Stock Price

16,54 BRL

6.45% ROA

9.34% ROE

25.45x PER

Market Cap.

7.086.799.697,00 BRL

78.75% DER

2.5% Yield

6.55% NPM

Fleury S.A. Stock Analysis

Fleury S.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Fleury S.A. Fundamental Stock Analysis
# Analysis Rating
1 Revenue Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

2 Assets Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

3 Dividend

The company's consistent dividend payouts over the past five years exemplify its strong commitment to providing shareholders with reliable returns, making it an attractive investment option.

4 ROE

The stock's ROE falls within an average range (9.46%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (5.14%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

6 PBV

The stock's PBV ratio (1.83x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

7 DER

The stock maintains a fair debt to equity ratio (83%), indicating a reasonable balance between the money it owes and the ownership it possesses.

8 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (273) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

9 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

10 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

11 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

Fleury S.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Fleury S.A. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Fleury S.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Fleury S.A. Revenue
Year Revenue Growth
2006 487.588.000
2007 551.230.000 11.55%
2008 675.280.000 18.37%
2009 770.109.000 12.31%
2010 871.541.000 11.64%
2011 1.125.741.000 22.58%
2012 1.501.783.000 25.04%
2013 1.656.896.000 9.36%
2014 1.678.900.000 1.31%
2015 1.894.960.000 11.4%
2016 2.096.113.000 9.6%
2017 2.383.012.000 12.04%
2018 2.664.463.000 10.56%
2019 2.905.107.000 8.28%
2020 2.971.616.000 2.24%
2021 3.872.651.000 23.27%
2022 4.463.040.000 13.23%
2023 7.480.180.000 40.34%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Fleury S.A. Research and Development Expenses
Year Research and Development Expenses Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Fleury S.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2006 106.393.000
2007 111.449.000 4.54%
2008 157.252.000 29.13%
2009 182.038.000 13.62%
2010 196.234.000 7.23%
2011 225.914.000 13.14%
2012 56.834.000 -297.5%
2013 58.685.000 3.15%
2014 58.420.000 -0.45%
2015 66.323.000 11.92%
2016 69.760.000 4.93%
2017 40.906.000 -70.54%
2018 46.046.000 11.16%
2019 51.764.000 11.05%
2020 61.782.000 16.22%
2021 104.350.000 40.79%
2022 103.834.000 -0.5%
2023 138.740.000 25.16%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Fleury S.A. EBITDA
Year EBITDA Growth
2006 85.267.000
2007 92.293.000 7.61%
2008 153.587.000 39.91%
2009 179.322.000 14.35%
2010 201.577.000 11.04%
2011 199.572.000 -1%
2012 290.009.000 31.18%
2013 268.412.000 -8.05%
2014 313.210.000 14.3%
2015 365.180.000 14.23%
2016 470.243.000 22.34%
2017 610.584.000 22.98%
2018 673.861.000 9.39%
2019 864.498.000 22.05%
2020 823.184.000 -5.02%
2021 1.060.023.000 22.34%
2022 1.267.433.000 16.36%
2023 2.064.352.000 38.6%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Fleury S.A. Gross Profit
Year Gross Profit Growth
2006 208.023.000
2007 223.459.000 6.91%
2008 282.761.000 20.97%
2009 318.424.000 11.2%
2010 364.154.000 12.56%
2011 392.503.000 7.22%
2012 403.253.000 2.67%
2013 371.976.000 -8.41%
2014 399.979.000 7%
2015 502.886.000 20.46%
2016 601.051.000 16.33%
2017 736.076.000 18.34%
2018 808.501.000 8.96%
2019 888.392.000 8.99%
2020 809.729.000 -9.71%
2021 1.126.893.000 28.14%
2022 1.210.110.000 6.88%
2023 2.110.260.000 42.66%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Fleury S.A. Net Profit
Year Net Profit Growth
2006 32.112.000
2007 25.315.000 -26.85%
2008 41.962.000 39.67%
2009 83.685.000 49.86%
2010 130.001.000 35.63%
2011 100.647.000 -29.17%
2012 106.588.000 5.57%
2013 61.143.000 -74.33%
2014 85.802.000 28.74%
2015 107.343.000 20.07%
2016 228.749.000 53.07%
2017 320.618.000 28.65%
2018 331.585.000 3.31%
2019 312.317.000 -6.17%
2020 256.961.000 -21.54%
2021 349.926.000 26.57%
2022 307.908.000 -13.65%
2023 696.792.000 55.81%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Fleury S.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 1 0%
2020 1 0%
2021 1 100%
2022 1 0%
2023 1 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Fleury S.A. Free Cashflow
Year Free Cashflow Growth
2006 43.968.000
2007 -11.257.000 490.58%
2008 -8.160.000 -37.95%
2009 -53.900.000 84.86%
2010 52.949.000 201.8%
2011 -38.291.000 238.28%
2012 4.209.000 1009.74%
2013 61.529.000 93.16%
2014 167.761.000 63.32%
2015 257.225.000 34.78%
2016 329.886.000 22.03%
2017 234.018.000 -40.97%
2018 375.142.000 37.62%
2019 524.461.000 28.47%
2020 459.325.000 -14.18%
2021 605.380.000 24.13%
2022 574.047.000 -5.46%
2023 393.510.000 -45.88%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Fleury S.A. Operating Cashflow
Year Operating Cashflow Growth
2006 71.329.000
2007 79.480.000 10.26%
2008 72.398.000 -9.78%
2009 24.031.000 -201.27%
2010 112.919.000 78.72%
2011 145.960.000 22.64%
2012 167.054.000 12.63%
2013 209.585.000 20.29%
2014 285.709.000 26.64%
2015 368.922.000 22.56%
2016 513.870.000 28.21%
2017 529.607.000 2.97%
2018 701.485.000 24.5%
2019 732.317.000 4.21%
2020 647.141.000 -13.16%
2021 1.018.669.000 36.47%
2022 987.133.000 -3.19%
2023 480.804.000 -105.31%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Fleury S.A. Capital Expenditure
Year Capital Expenditure Growth
2006 27.361.000
2007 90.737.000 69.85%
2008 80.558.000 -12.64%
2009 77.931.000 -3.37%
2010 59.970.000 -29.95%
2011 184.251.000 67.45%
2012 162.845.000 -13.15%
2013 148.056.000 -9.99%
2014 117.948.000 -25.53%
2015 111.697.000 -5.6%
2016 183.984.000 39.29%
2017 295.589.000 37.76%
2018 326.343.000 9.42%
2019 207.856.000 -57%
2020 187.816.000 -10.67%
2021 413.289.000 54.56%
2022 413.086.000 -0.05%
2023 87.294.000 -373.21%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Fleury S.A. Equity
Year Equity Growth
2006 98.260.000
2007 96.685.000 -1.63%
2008 150.673.000 35.83%
2009 846.339.000 82.2%
2010 1.011.803.000 16.35%
2011 1.631.881.000 38%
2012 1.705.908.000 4.34%
2013 1.689.033.000 -1%
2014 1.572.964.000 -7.38%
2015 1.655.439.000 4.98%
2016 1.535.725.000 -7.8%
2017 1.706.528.000 10.01%
2018 1.749.961.000 2.48%
2019 1.758.976.000 0.51%
2020 1.750.850.000 -0.46%
2021 1.854.483.000 5.59%
2022 2.701.085.000 31.34%
2023 5.191.945.000 47.98%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Fleury S.A. Assets
Year Assets Growth
2006 326.114.000
2007 505.942.000 35.54%
2008 616.760.000 17.97%
2009 1.264.469.000 51.22%
2010 1.328.168.000 4.8%
2011 2.831.721.000 53.1%
2012 2.738.159.000 -3.42%
2013 3.211.167.000 14.73%
2014 3.209.768.000 -0.04%
2015 3.203.997.000 -0.18%
2016 3.005.820.000 -6.59%
2017 3.527.332.000 14.78%
2018 3.910.448.000 9.8%
2019 5.096.652.000 23.27%
2020 5.523.810.000 7.73%
2021 6.073.770.000 9.05%
2022 7.791.770.000 22.05%
2023 11.533.043.000 32.44%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Fleury S.A. Liabilities
Year Liabilities Growth
2006 220.204.000
2007 404.595.000 45.57%
2008 464.921.000 12.98%
2009 418.130.000 -11.19%
2010 316.365.000 -32.17%
2011 1.199.840.000 73.63%
2012 1.032.251.000 -16.24%
2013 1.522.134.000 32.18%
2014 1.636.804.000 7.01%
2015 1.548.558.000 -5.7%
2016 1.470.095.000 -5.34%
2017 1.820.804.000 19.26%
2018 2.160.487.000 15.72%
2019 3.337.676.000 35.27%
2020 3.772.960.000 11.54%
2021 4.219.287.000 10.58%
2022 5.090.685.000 17.12%
2023 6.341.098.000 19.72%

Fleury S.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
10.76
Net Income per Share
0.68
Price to Earning Ratio
25.45x
Price To Sales Ratio
1.21x
POCF Ratio
7.36
PFCF Ratio
7.88
Price to Book Ratio
1.84
EV to Sales
1.9
EV Over EBITDA
6.89
EV to Operating CashFlow
8.64
EV to FreeCashFlow
12.4
Earnings Yield
0.04
FreeCashFlow Yield
0.13
Market Cap
7,09 Bil.
Enterprise Value
11,15 Bil.
Graham Number
12.06
Graham NetNet
-7.4

Income Statement Metrics

Net Income per Share
0.68
Income Quality
3.49
ROE
0.09
Return On Assets
0.04
Return On Capital Employed
0.09
Net Income per EBT
0.8
EBT Per Ebit
0.58
Ebit per Revenue
0.14
Effective Tax Rate
0.21

Margins

Sales, General, & Administrative to Revenue
0.02
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.26
Operating Profit Margin
0.14
Pretax Profit Margin
0.08
Net Profit Margin
0.07

Dividends

Dividend Yield
0.03
Dividend Yield %
2.5
Payout Ratio
0.33
Dividend Per Share
0.43

Operating Metrics

Operating Cashflow per Share
2.36
Free CashFlow per Share
1.64
Capex to Operating CashFlow
-0.3
Capex to Revenue
-0.07
Capex to Depreciation
-0.64
Return on Invested Capital
0.06
Return on Tangible Assets
0.06
Days Sales Outstanding
103.49
Days Payables Outstanding
48.92
Days of Inventory on Hand
11.5
Receivables Turnover
3.53
Payables Turnover
7.46
Inventory Turnover
31.75
Capex per Share
-0.72

Balance Sheet

Cash per Share
1,79
Book Value per Share
9,47
Tangible Book Value per Share
-1.01
Shareholders Equity per Share
9.47
Interest Debt per Share
8.3
Debt to Equity
0.79
Debt to Assets
0.35
Net Debt to EBITDA
2.51
Current Ratio
1.48
Tangible Asset Value
-0,55 Bil.
Net Current Asset Value
-3,50 Bil.
Invested Capital
0.79
Working Capital
0,92 Bil.
Intangibles to Total Assets
0.5
Average Receivables
1,64 Bil.
Average Payables
0,58 Bil.
Average Inventory
133830000
Debt to Market Cap
0.58

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Fleury S.A. Dividends
Year Dividends Growth
2010 0
2011 0 0%
2012 0 0%
2013 1 0%
2014 1 100%
2015 0 0%
2016 2 100%
2017 1 0%
2018 1 0%
2019 1 100%
2020 1 0%
2021 1 0%
2022 1 100%
2023 0 0%

Fleury S.A. Profile

About Fleury S.A.

Fleury S.A., together with its subsidiaries, provides medical services in the diagnostic, treatment, clinical analysis, health management, medical care, orthopedics, and ophthalmology areas in Brazil. The company operates through three segments: Diagnostic Medicine, Integrated Medicine, and Dental. It provides laboratory and image exam, diagnostic information, check-up and reference laboratory, genomics, clinic day, center of infusions, dental imaging exam, dental radiology, and diagnostic imaging services. The company also offers Saúde I, a digital healthcare platform that provides services, including teleconsultations, medical, diagnostic medicine exams, and procedures; and corporate solutions and face-to-face primary care, as well as solutions for physicians with digital office and medical education. It operates 284 customer service units and 31 hospital-based units under the Labs a+, Felippe Mattoso, Lafe, Fleury, a+SP, CIP, Moacir Cunha, Vita, inlab, Weinmann, Serdil, a+ and Diagmax, a+, IRN / CPC, Diagnosis a+, a+BA, and Pretti and Bioclinic brand names. The company was founded in 1926 and is headquartered in São Paulo, Brazil.

CEO
Ms. Jeane Mike Tsutsui
Employee
27.300
Address
Avenida General Valdomiro de Lima, 508
São Paulo, 04344-903

Fleury S.A. Executives & BODs

Fleury S.A. Executives & BODs
# Name Age
1 Mr. Fernando Aguiar Camargo
Secretary
70
2 Mr. Edgar Gil Rizzatti
Medical, Technical & Process Executive Director and Member of Executive Board
70
3 Ms. Jeane Mike Tsutsui
Chief Executive Officer & President of Executive Board
70
4 Mr. Jose Antonio de Almeida Filippo
Chief Financial Officer, Investor Relations Officer & Member of Executive Board
70
5 Mr. Claudio Almeida Prado
Executive Director of New Links & Member of Executive Board
70
6 Mr. Roberto Santoro Meirelles
L2L & Operations Support Officer and Member of Executive Board
70

Fleury S.A. Competitors